Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:1
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [41] Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer
    Cheng, Xiangming
    Liu, Xiaoyan
    Liu, Xiang
    Guo, Zhengguang
    Sun, Haidan
    Zhang, Mingxin
    Ji, Zhigang
    Sun, Wei
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [42] Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage
    Grimberg, Dominic C.
    Dudinec, John
    Shah, Ankeet
    Inman, Brant A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (08) : 498.e13 - 498.e20
  • [43] Experience with Newer Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer
    LaMont J. Barlow
    Mitchell C. Benson
    Current Urology Reports, 2013, 14 : 65 - 70
  • [44] THERMAL INTRAVESICAL CHEMOTHERAPY IN ADJUVANT TREATMENT OF HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER
    Efiloglu, Ozgur
    Bayrak, Omer
    Turan, Turgay
    Kazan, Huseyin Ozgur
    Culpan, Meftun
    Cakici, Mehmet Caglar
    Erturhan, Sakip
    Yildirim, Asif
    ARCHIVOS ESPANOLES DE UROLOGIA, 2021, 74 (09): : 875 - 882
  • [45] Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer
    Lerner, Seth P.
    Tangen, Catherine M.
    Sucharew, Heidi
    Wood, David
    Crawford, E. David
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (02) : 155 - 159
  • [46] T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy
    E. De Berardinis
    G. M. Busetto
    G. Antonini
    R. Giovannone
    V. Gentile
    International Urology and Nephrology, 2011, 43 : 1047 - 1057
  • [47] Can the systemic immune inflammation index be a predictor of BCG response in patients with high-risk non-muscle invasive bladder cancer?
    Akan, Serkan
    Ediz, Caner
    Sahin, Aytac
    Tavukcu, Hasan Huseyin
    Urkmez, Ahmet
    Horasan, Alper
    Yilmaz, Omer
    Verit, Ayhan
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (04)
  • [48] Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer
    Benderska-Soder, Natalya
    Ecke, Thorsten
    Kleinlein, Lisa
    Roghmann, Florian
    Bismarck, Ekkehardt
    van Rhijn, Bas W. G.
    Stenzl, Arnulf
    Witjes, Johannes Alfred
    Todenhoefer, Tilman
    Hakenberg, Oliver W.
    Grimm, Marc Oliver
    Goebell, Peter J.
    Burger, Maximilian
    Jensen, Jorgen Bjerggaard
    Schmitz-Draeger, Bernd J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (08) : 229 - 235
  • [49] A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer
    Sousa, Alejandro
    Inman, Brant A.
    Pineiro, Idelfonso
    Monserrat, Victor
    Perez, Alberto
    Aparici, Vincente
    Gomez, Isabel
    Neira, Pilar
    Uribarri, Carlos
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2014, 30 (03) : 166 - 170
  • [50] Diagnostic biomarkers in non-muscle invasive bladder cancer
    Izak Faiena
    Charles J. Rosser
    Karim Chamie
    Hideki Furuya
    World Journal of Urology, 2019, 37 : 2009 - 2016